Long non‑coding RNA TMCC1‑AS1 predicts poor prognosis and accelerates epithelial‑mesenchymal transition in liver cancer

Chen,Cheng; Su,Na; Li,Guiying; Shen,Yanfeng; Duan,Xiaoting

doi:10.3892/ol.2021.13034

Long non‑coding RNA TMCC1‑AS1 predicts poor prognosis and accelerates epithelial‑mesenchymal transition in liver cancer

Authors:
- Cheng Chen
- Na Su
- Guiying Li
- Yanfeng Shen
- Xiaoting Duan
View Affiliations

Affiliations: Oncology Department II, Affiliated Hospital of Hebei Engineering University, Handan, Hebei 056000, P.R. China, Department of Nephrology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei 056000, P.R. China
Published online on: September 9, 2021 https://doi.org/10.3892/ol.2021.13034
Article Number: 773
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA transmembrane and coiled‑coil domain family 1 antisense RNA 1 (TMCC1‑AS1) has been frequently reported to be associated with prognosis in patients with liver cancer (LC). However, the biological role of TMCC1‑AS1 in LC in vitro remains unclear. The expression levels of TMCC1‑AS1 in primary tumor tissues and LC cell lines were determined using reverse transcription‑quantitative PCR. The associations between TMCC1‑AS1 expression and the clinicopathological factors of patients with LC were statistically analyzed using the χ² test. The role of TMCC1‑AS1 in LC prognosis was assessed using Kaplan‑Meier curves and proportional hazards model (Cox) analysis. Cell proliferation was determined by Cell Counting Kit‑8 and colony formation assays. Transwell assays were performed to determine migration and invasion. TMCC1‑AS1 expression was found to be significantly upregulated in LC tissues and cell lines compared with the corresponding controls. High TMCC1‑AS1 expression was associated with advanced TNM stage and lymph node metastasis. Furthermore, high TMCC1‑AS1 expression predicted poor survival in patients with LC. Knockdown of TMCC1‑AS1 significantly inhibited the proliferation, migration and invasion of HepG2 and SNU‑182 cells, while overexpression of TMCC1‑AS1 had the opposite effect in HepG2 and SNU‑182 cells. At the molecular level, downregulation of TMCC1‑AS1 expression resulted in increased E‑cadherin expression and decreased proliferating cell nuclear antigen, Ki67, N‑cadherin and Vimentin expression in HepG2 cells. Overexpression of TMCC1‑AS1 had the opposite effects on these factors in SNU‑182 cells. In conclusion, the present findings indicated that TMCC1‑AS1 might be considered as a novel oncogene, which promotes cell proliferation and migration, and may be a potential therapeutic target for LC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
3	Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF and McGlynn KA: Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 122:1757–1765. 2016. View Article : Google Scholar : PubMed/NCBI
4	Jain D, Nayak NC, Kumaran V and Saigal S: Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: A study from India. Arch Pathol Lab Med. 137:961–966. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hartke J, Johnson M and Ghabril M: The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
6	Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg. 243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
7	Moran VA, Perera RJ and Khalil AM: Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 40:6391–6400. 2012. View Article : Google Scholar : PubMed/NCBI
8	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang Z, Wang S, Yang F, Meng Z and Liu Y: LncRNA ROR1-AS1 high expression and its prognostic significance in liver cancer. Oncol Rep. 43:55–74. 2020.PubMed/NCBI
10	Xu J, Lu Y, Liu Q, Xia A, Zhao J, Xu X, Sun Q, Qi F and Sun B: Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with eIF4B. Cancer Lett. 473:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
11	Luo Y, Lin J, Zhang Y, Dai G, Li A and Liu X: LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis. Cell Biochem Funct. 38:895–904. 2020. View Article : Google Scholar : PubMed/NCBI
12	Yu J, Ou Z, Lei Y, Chen L, Su Q and Zhang K: LncRNA MYCNOS facilitates proliferation and invasion in hepatocellular carcinoma by regulating miR-340. Hum Cell. 33:148–158. 2020. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Ding X, Xiu S, Du G and Liu Y: LncRNA NEAT1 promotes proliferation, migration and invasion via regulating miR-296-5p/CNN2 axis in hepatocellular carcinoma cells. Onco Targets Ther. 12:9887–9897. 2019. View Article : Google Scholar : PubMed/NCBI
14	Huang W, Huang F, Lei Z and Luo H: LncRNA SNHG11 promotes proliferation, migration, apoptosis, and autophagy by regulating hsa-miR-184/AGO2 in HCC. Onco Targets Ther. 13:413–421. 2020. View Article : Google Scholar : PubMed/NCBI
15	Pu J, Wang J, Wei H, Lu T, Wu X, Wu Y, Shao Z, Luo C and Lu Y: lncRNA MAGI2-AS3 prevents the development of HCC via recruiting KDM1A and promoting H3K4me2 demethylation of the RACGAP1 promoter. Mol Ther Nucleic Acids. 18:351–362. 2019. View Article : Google Scholar : PubMed/NCBI
16	Zhou Y, Huan L, Wu Y, Bao C, Chen B, Wang L, Huang S, Liang L and He X: LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Lett. 469:399–409. 2020. View Article : Google Scholar : PubMed/NCBI
17	Bo C, Li X, He L, Zhang S, Li N and An Y: A novel long noncoding RNA HHIP-AS1 suppresses hepatocellular carcinoma progression through stabilizing HHIP mRNA. Biochem Biophys Res Commun. 520:333–340. 2019. View Article : Google Scholar : PubMed/NCBI
18	Cui H, Zhang Y, Zhang Q, Chen W, Zhao H and Liang J: A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. Cancer Med. 6:2932–2941. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zhao QJ, Zhang J, Xu L and Liu FF: Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol. 24:3426–3439. 2018. View Article : Google Scholar : PubMed/NCBI
20	Deng B, Yang M, Wang M and Liu Z: Development and validation of 9-long non-coding RNA signature to predicting survival in hepatocellular carcinoma. Medicine (Baltimore). 99:e204222020. View Article : Google Scholar : PubMed/NCBI
21	Greene FL: The American joint committee on cancer: Updating the strategies in cancer staging. Bull Am Coll Surg. 87:13–15. 2002.PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
25	Howley BV and Howe PH: TGF-beta signaling in cancer: Post-transcriptional regulation of EMT via hnRNP E1. Cytokine. 118:19–26. 2019. View Article : Google Scholar : PubMed/NCBI
26	E C, Yang J, Li H and Li C: LncRNA LOC105372579 promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma via activating miR-4316/FOXP4 signaling. Cancer Manag Res. 11:2871–2879. 2019. View Article : Google Scholar : PubMed/NCBI
27	Guo D, Li Y, Chen Y, Zhang D, Wang X, Lu G, Ren M, Lu X and He S: DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway. Cell Prolif. 52:e126282019. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C, Dou C, Xu M, Liu Q and Tu K: Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 16:1232017. View Article : Google Scholar : PubMed/NCBI
29	Zhu L, Yang N, Du G, Li C, Liu G, Liu S, Xu Y, Di Y, Pan W and Li X: LncRNA CRNDE promotes the epithelial-mesenchymal transition of hepatocellular carcinoma cells via enhancing the Wnt/β-catenin signaling pathway. J Cell Biochem. 120:1156–1164. Nov 14–2018. View Article : Google Scholar : PubMed/NCBI